Geron (NASDAQ:GERN) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Geron (NASDAQ:GERN) in a report released on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $8.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Geron’s Q3 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.36) EPS and FY2025 earnings at ($0.23) EPS.

A number of other brokerages have also recently commented on GERN. StockNews.com upgraded Geron to a “sell” rating in a research note on Monday, August 5th. Leerink Partnrs raised Geron to a “strong-buy” rating in a research report on Monday, September 9th. Scotiabank started coverage on shares of Geron in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Geron in a report on Thursday, August 8th. Finally, Leerink Partners started coverage on Geron in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.05.

Geron Stock Down 0.7 %

GERN opened at $4.22 on Tuesday. Geron has a 1 year low of $1.64 and a 1 year high of $5.34. The firm has a 50 day moving average price of $4.33 and a 200 day moving average price of $4.30. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61. The company has a market cap of $2.54 billion, a PE ratio of -11.72 and a beta of 0.52.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The company had revenue of $0.88 million during the quarter, compared to analyst estimates of $0.34 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The business’s quarterly revenue was up 2941.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.09) earnings per share. Sell-side analysts expect that Geron will post -0.34 earnings per share for the current year.

Institutional Investors Weigh In On Geron

A number of institutional investors have recently modified their holdings of the business. National Bank of Canada FI raised its position in shares of Geron by 1,200.0% during the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 6,000 shares during the period. Crewe Advisors LLC grew its stake in Geron by 870.0% during the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 8,700 shares during the last quarter. Kingsview Wealth Management LLC acquired a new stake in Geron in the first quarter worth $34,000. American Trust bought a new stake in Geron in the first quarter valued at $38,000. Finally, Rovin Capital UT ADV acquired a new position in shares of Geron during the third quarter valued at $62,000. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.